Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod 5% Cream for Infantile Hemangioma
NCT00601016Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire Sainte-Justine
- Start
- Mar 2005
- Primary completion
- Sep 2006
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imiquimod in infantile hemangioma (IH), sponsored by Centre Hospitalier Universitaire Sainte-Justine. Primary endpoint: Efficacy of Imiquimod 5% cream at 4 months. Started Mar 2005; status: completed.
02
Drugs
imiquimod
03
Conditions
infantile hemangioma (IH)
Beyond the preview
Go deeper on NCT00601016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00601016.